2-(2-氨基乙基)-1H-异吲哚-1,3(2H-)-二酮盐酸盐 | 30250-67-0

• 物质功能分类: 生物 - 细胞培养 - 添加剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 中文名称: 2-(2-氨基乙基)-1H-异吲哚-1,3(2H-)-二酮盐酸盐
• 中文别名: N-(2-氨乙基)-邻苯二甲酰亚胺盐酸盐；N-(2-氨基乙基)苯二甲酰亚胺盐酸盐
• 英文名称: 2-(2-aminoethyl)isoindoline-1,3-dione hydrochloride
• 英文别名: 2-phthalimido-ethylamine hydrochloride；N-(2-amino-ethyl)phthalimide hydrochloride；2-(2-aminoethyl)isoindole-1,3-dione;hydrochloride
• CAS: 30250-67-0
• 化学式: C₁₀H₁₀N₂O₂*ClH
• mdl: MFCD08272836
• 分子量: 226.663
• InChiKey: UIRMSBGEEQIABR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.12
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  63.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2925190090
• 危险标志：
  GHS05
• 危险性描述：
  H318
• 危险性防范说明：
  P280,P305 + P351 + P338
• 储存条件：
  室温和干燥环境中使用。

反应信息

• 作为反应物：
  描述：

  2-(2-氨基乙基)-1H-异吲哚-1,3(2H-)-二酮盐酸盐 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.5h， 生成 (2,3,4,5,6-Pentafluorophenyl) 2-[2-[2-(1,3-dioxoisoindol-2-yl)ethylamino]-2-oxoethyl]sulfanylacetate
  参考文献：
  名称：

  WO2019183577A5

  摘要：

  公开号：

  WO2019183577A5
• 作为产物：
  描述：

  N-[2-(2-硝基-1H-咪唑基)乙基]邻苯二甲酰亚胺 在 hydrochloric acid diethyl ether 、 一水合肼 作用下， 以 乙醇 为溶剂， 生成 2-(2-氨基乙基)-1H-异吲哚-1,3(2H-)-二酮盐酸盐
  参考文献：
  名称：

  Synthesis and Bioevaluation of Novel [¹⁸F]FDG-Conjugated 2-Nitroimidazole Derivatives for Tumor Hypoxia Imaging

  摘要：

  Hypoxia imaging can guide tumor treatment and monitor changes in hypoxia during treatment. However, there is still no ideal hypoxia imaging agent for clinical applications. In this study, two novel 2-nitromidazole derivatives were synthesized and directly radiolabeled by [F-18]FDG in high radiochemical yield and excellent radiochemical purity. Cell experiments, biodistribution, and positron emission tomography (PET) imaging studies were also conducted in mice-bearing S180 or OS732 tumors. [F-18]FDG-2NNC2ON [(2R,3S,4R,E)-2-F-18-fluoro-3,4,5,6-tetrahydroxyhexanal O-3-(2-(2-nitro-1H-imidazole-1-yl)ethylamino)-2-oxopropyl oxime] and [F-18]FDG-2NNCSON [(2R,3S,4R,E)-2-F-18-fluoro-3,4,5,6-tetrahydroxyhexanal-O-3-(5-(2-nitro-1H-imidazole-1-yl)entylamino)-2-oxopropyl oxime] can be cleared from the blood quickly and specifically target hypoxic tumor cells. The uptake of the probes by hypoxic cells gradually increases with time. After 4 h, the uptake value of [F-18]FDG-2NNC2ON in hypoxic cells is 3.2 times higher than that in normoxia cells. In contrast, there is no difference in the uptake of [F-18]FDG between hypoxic cells and normoxia cells. Biodistribution resulting from two tumor models indicate that the uptake values of the two radiotracers in the tumor are higher at 1 h than those at 2 and 4 h. At 1 and 2 h, the tumors are clearly observed on the PET images and the imaging features of [F-18]FDG-2NNC5ON and [F-18]FDG-2NNC2ON are distinct from those of [F-18]FDG. Compared with [F-18]FDG-2NNC5ON, [F-18]FDG-2NNC2ON has a higher proportion of renal excretion, lower digestive tract uptake, and better imaging contrast because of its higher hydrophilicity. At 2 h, [F-18]FDG-2NNC2ON shows a good tumor-to-blood (T/B) ratio, tumor-to-muscle ratio based on biodistribution (Bio-T/M ratio), and tumor-to-muscle ratio based on regions of interest on the PET images [region of interest (ROI)-T/M ratio] in the two tumor models (T/B, Bio-T/M, and ROI-T/M ratios are 3.2, 2.6, and 3.9 in the S180 tumor model and are 3.4, 4.2, and 4.6 in the OS732 tumor model, respectively). The imaging features visualized with autoradiography mostly coincided with the positive areas of HIF1 alpha staining by immunofluorescence. Meanwhile, the biodistribution study and PET imaging revealed that the uptake of the radiotracers in the tumor cannot be competed by 5% glucose, confirming that [F-18]FDG-2NNC2ON targets the hypoxic regions of the tumors instead of targeting tumors through the glucose metabolism pathway. These results suggest that the new 2-nitroimidazole derivative conjugated with [F-18]FDG, [F-18]FDG-2NNC2ON, has potential as an imaging agent for hypoxia.

  DOI：

  10.1021/acs.molpharmaceut.9b00075

文献信息

• INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHEREIN THE PI IS COMPRISED FORM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS
  申请人：ADOCIA

  公开号：US20190275115A1

  公开（公告）日：2019-09-12

  In one embodiment, the composition according to the invention is characterized in that the co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical -Hy is chosen among the co-polyamino acids according to formula XXXb hereinafter: wherein, D represents, independently, either a group —CH 2 — (aspartic acid) or a group —CH 2 —CH 2 — (glutamic acid), X represents a cationic entity chosen in the group comprising alkali cations, R b and R b ′, identical or different, are either a hydrophobic radical -Hy, or a radical chosen in the group consisting of an H, a C2 to C10 linear acyl group, a C3 to C10 branched acyl group, a benzyl, a terminal “amino acid” unit and a pyroglutamate, at least one of Rb and R′b is a hydrophobic radical -Hy, Q and Hy are as defined above. n+m represents the degree of polymerization DP of the co-polyamino acid, namely the mean number of monomeric units per co-polyamino acid chain and 5≤n+m≤250.

  在一种实施例中，根据本发明的组合物的特征在于，共聚氨基酸带有羧酸盐基团和至少一种疏水基团-Hy，所述疏水基团-Hy是从下文公式XXXb中的共聚氨基酸中选择的： 其中， D分别表示一个基团—CH 2 —（天冬氨酸）或一个基团—CH 2 —CH 2 —（谷氨酸）， X表示从包括碱金属阳离子在内的阳离子实体中选择的一个阳离子实体， R b 和R b ′，相同或不同，要么是一个疏水基团-Hy，要么是从包括H、C2到C10线性酰基团、C3到C10支链酰基团、苄基、末端“氨基酸”单元和吡咯谷氨酸在内的基团中选择的一个基团， Rb和R′b中至少一个是疏水基团-Hy， Q和Hy如上所定义。 n+m表示共聚氨基酸的聚合度DP，即每个共聚氨基酸链上的单体单位的平均数，且5≤n+m≤250。
• Synthesis of N-trifluoromethyl amides from carboxylic acids
  作者：Jianbo Liu、Matthew F.L. Parker、Sinan Wang、Robert R. Flavell、F. Dean Toste、David M. Wilson

  DOI：10.1016/j.chempr.2021.07.005

  日期：2021.8

  frequently found in pharmaceutical compounds. To date, there is no strategy for synthesizing N-trifluoromethyl amides from abundant organic carboxylic acid derivatives, which are ideal starting materials in amide synthesis. Here, we report the synthesis of N-trifluoromethyl amides from carboxylic acid halides and esters under mild conditions via isothiocyanates in the presence of silver fluoride at room temperature

  在生物分子、药物和农用化学品中发现的含酰胺分子在自然界中无处不在，它们的衍生化代表了氟化学的重要方法学目标。三氟甲基酰胺已成为药物化合物中常见的重要官能团。迄今为止，还没有从丰富的有机羧酸衍生物合成N-三氟甲基酰胺的策略，有机羧酸衍生物是酰胺合成的理想原料。在这里，我们报告了N的合成-三氟甲基酰胺从羧酸卤化物和酯在温和条件下通过异硫氰酸酯在氟化银存在下在室温下。通过这种策略，异硫氰酸酯用 AgF 脱硫，然后将形成的衍生物酰化以提供N-三氟甲基酰胺，包括以前无法获得的结构。该方法适用范围广，凭借两个反应伙伴的多样性和可用性，为快速生成N-三氟甲基酰胺提供了平台，并应在高级中间体的改性中找到应用。
• COMPOSITIONS SOUS FORME D'UNE SOLUTION AQUEUSE INJECTABLE COMPRENANT DU GLUCAGON HUMAIN ET UN CO-POLYAMINOACIDE
  申请人：ADOCIA

  公开号：US20190275156A1

  公开（公告）日：2019-09-12

  Physically stable compositions in the form of an injectable aqueous solution, wherein the pH is from 6.0 to 8.0, includes at least: a) human glucagon and b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy. In one embodiment, the compositions further comprise a gut hormone.

  在形式为可注射的水溶液中，具有稳定的物理性质，其中pH值为6.0至8.0，至少包括： a) 人类胰高血糖素和 b) 具有羧酸基团和疏水基团Hy的共聚氨基酸。在一个实施例中，这些组合物进一步包括一种肠道激素。
• Novel benzimidazole anti-inflammatory compounds
  申请人：Pfizer Inc.

  公开号：US20030092749A1

  公开（公告）日：2003-05-15

  The present invention relates to novel triazolo-pyridines of the formula I 1 wherein Het is an optionally substituted 5 -membered heterocycle containing one to two heteroatoms selected from nitrogen, sulfur and oxygen wherein at least one of said heteroatoms atoms must be nitrogen; R 2 is selected from the group consisting of hydrogen, (C 1 -C 6 )alkyl or other suitable substituents; R 3 is selected from the group consisting of hydrogen, (C 1 -C6)alkyl or other suitable substituents; s is an integer from 0-5; to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, repurfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

  本发明涉及公式I的新型三唑基吡啶 其中Het是一个可选择取代的 含有一个到两个氮、硫和氧杂原子的5元杂环，其中至少一个杂原子必须是氮; R 2 选自由氢、(C 1 -C 6 )烷基或其他适当的取代基组成的群; R 3 选自由氢、(C 1 -C6)烷基或其他适当的取代基组成的群; s是0-5之间的整数; 用于它们的制备的中间体，含有它们的药物组合物以及它们的药用。本发明的化合物是MAP激酶，优选为p38激酶的有效抑制剂。它们在治疗炎症、骨关节炎、类风湿性关节炎、癌症、中风或心脏病发中的再灌注或缺血、自身免疫疾病和其他疾病中有用。
• Substituted Heterocyclic Mercaptosulfonamide Metalloprotease Inhibitors
  申请人：Schwartz Martin A.

  公开号：US20110144179A1

  公开（公告）日：2011-06-16

  The present invention generally relates to substituted heterocyclic mercaptosulfonamide compounds, precursors, and derivatives as well as methods for the preparation of and pharmaceutical compositions comprising these compounds. These compounds are designed to be potent selective inhibitors of matrix metalloproteinases (MMPs), including, for example, gelatinases, collagenases, matrilysins, metalloelastase, stromelysin, and membrane-type 1 matrix metalloproteinase. These inhibitors may be used for the control of physiological and pathological processes and disease conditions in which MMPs are believed to play significant functions.

  本发明一般涉及取代的杂环巯基磺酰胺化合物、前体及其衍生物，以及制备这些化合物的方法和包含这些化合物的药物组合物。这些化合物被设计为强效的选择性基质金属蛋白酶（MMPs）抑制剂，包括例如明胶酶、胶原酶、基质溶素、金属弹性蛋白酶、基质溶素和膜型1基质金属蛋白酶。这些抑制剂可用于控制生理和病理过程以及疾病状况，在这些过程中，MMPs被认为发挥着重要作用。